Latest

24
May
ICER: The Gatekeeper of European Healthcare, or a Flawed Oracle?

ICER: The Gatekeeper of European Healthcare, or a Flawed Oracle?

The Incremental Cost-Effectiveness Ratio (ICER) is the darling of health economists and the bane of pharmaceutical companies. At its heart,
3 min read
23
May
In a Hole in the Budget There Lived a KOL

In a Hole in the Budget There Lived a KOL

Not a nasty, dirty, wet hole, nor yet a humble one. This was a suite at the Four Seasons, with
3 min read
22
May
The Problem with Markov Models

The Problem with Markov Models

Markov models have become a default tool in drug development, used for modeling disease progression, treatment outcomes, and cost-effectiveness. While
3 min read
21
May
AI in Biotech: Taking Stock of a Decade of Progress and the Challenges Ahead

AI in Biotech: Taking Stock of a Decade of Progress and the Challenges Ahead

Artificial intelligence has had a profound decade in biotech, advancing from a promising academic endeavor to a critical driver of
3 min read
20
May
The Problem with Optimism Bias in Biotech Projections: A Quantitative and Probabilistic Analysis

The Problem with Optimism Bias in Biotech Projections: A Quantitative and Probabilistic Analysis

Optimism bias, the cognitive tendency to overestimate the likelihood of favorable outcomes and underestimate risks, is a pervasive issue in
3 min read
19
May
The Problem with Biotech’s Love Affair with Academia

The Problem with Biotech’s Love Affair with Academia

Biotech and academia are the original odd couple. One is driven by bold bets on untested science and the hope
4 min read
18
May
The Problem with “Trendy Science” in Biotech: Chasing the Next Big Thing

The Problem with “Trendy Science” in Biotech: Chasing the Next Big Thing

Biotech is the land of promise—and peril. Every few years, a new scientific breakthrough takes center stage, drawing billions
3 min read
17
May
Corporate Venture Funds and Strategic Partnerships: Friends, Benefactors, or Frenemies?

Corporate Venture Funds and Strategic Partnerships: Friends, Benefactors, or Frenemies?

For biotech startups, corporate venture funds (CVCs) are often painted as a dream come true—cash with benefits. You get
4 min read
16
May
The Ethics of Failure: The Uncomfortable Bedfellow

The Ethics of Failure: The Uncomfortable Bedfellow

The Ethics of Failure: Biotech’s Uncomfortable Bedfellow Failure is biotech’s least glamorous partner. It doesn’t show up
3 min read
15
May
The Meeting That Achieved Nothing—and Why That’s Sometimes Okay

The Meeting That Achieved Nothing—and Why That’s Sometimes Okay

Modern corporate life has evolved into a peculiar form of theatre: every actor dressed in Uniqlo smart casual, each line
3 min read